Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Determinants of participation in treatment decision-making by older breast cancer patients
Authors
Rose C. Maly
Yoshiko Umezawa
Barbara Leake
Rebecca A. Silliman
Publication date
01-06-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/B:BREA.0000025408.46234.66

Other articles of this Issue 3/2004

Breast Cancer Research and Treatment 3/2004 Go to the issue

Authors Index

Author Index, Volume 85

OriginalPaper

Use of complementary and alternative medicine by Chinese women with breast cancer

OriginalPaper

A Systematic Review of Intraoperative Radiotherapy in Early Breast Cancer

Report

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

OriginalPaper

Magnetic Resonance Imaging in Comparison to Clinical Palpation in Assessing the Response of Breast Cancer to Epirubicin Primary Chemotherapy

OriginalPaper

Three-dimensional in vitro tissue culture models of breast cancer — a review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits